Svar Life Science

September 21, 2023

Svar Supporting the EPND Initiative: Advancing Awareness and Treatment for Neurodegenerative Diseases on World Alzheimer's Day

Today,  World Alzheimer's Day, we join the community to raise awareness of the need for better care, support, and research to improve the lives of those affected by Alzheimer's and other forms of dementia. 

A major research effort is the European Platform for Neurodegenerative Diseases (EPND), a public-private partnership funded by the Innovative Medicines Initiative (IMI), a joint undertaking between the EU and European pharmaceutical industries supporting projects at the health research vanguard.

Svar is proud to be part of this collective effort to accelerate the understanding and management of neurodegenerative diseases. By combining our expertise with that of other partners in EPND, we hope to make significant strides towards improving the lives of patients and their families affected by debilitating conditions like Alzheimer's

September 21, 2023

Svar Supporting the EPND Initiative: Advancing Awareness and Treatment for Neurodegenerative Diseases on World Alzheimer's Day

Today,  World Alzheimer's Day, we join the community to raise awareness of the need for better care, support, and research to improve the lives of those affected by Alzheimer's and other forms of dementia. 

A major research effort is the European Platform for Neurodegenerative Diseases (EPND), a public-private partnership funded by the Innovative Medicines Initiative (IMI), a joint undertaking between the EU and European pharmaceutical industries supporting projects at the health research vanguard.

Svar is proud to be part of this collective effort to accelerate the understanding and management of neurodegenerative diseases. By combining our expertise with that of other partners in EPND, we hope to make significant strides towards improving the lives of patients and their families affected by debilitating conditions like Alzheimer's

 

Neurodegenerative diseases, such as Alzheimer's have become a significant global health concern. These diseases severely impact the lives of millions of people worldwide, causing progressive deterioration of cognitive and motor functions. Despite extensive research efforts, effective diagnostics and therapies for these diseases remain elusive.

By establishing a platform for data and sample sharing, the EPND aims to facilitate the discovery and validation of biomarkers that can aid in the early detection, accurate diagnosis, and monitoring of neurodegenerative diseases.

Svar is proud to contribute to the EPND initiative on the discovery of inflammatory and complement biomarkers for Alzheimer's and Parkinson's diseases. Inflammation and dysregulation of the complement system have been implicated in the pathogenesis of these diseases. Identifying and validating new biomarkers related to these processes will provide valuable tools for disease diagnosis and monitoring.

Our partnership in this project contributes to the establishment of a European infrastructure that facilitates access to clinical samples and data. Together, we strive to advance the understanding of Alzheimer's and Parkinson's diseases, and on World Alzheimer's Day, we emphasize the importance of research in finding effective solutions for these conditions.

The European Platform for Neurodegenerative Diseases (EPND) will integrate existing initiatives and build, grow, and deliver a scalable and self-sustainable platform for the storage and analysis of high-quality clinical and biological samples and data collections. This project aims to realize those promises in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, which cost millions of lives and will create an estimated economic burden of €267 billion in Europe by 2030.¹

1 (Maresova et al., 2016)
Learn more about EPND